Fmr LLC Buys 111,104 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Fmr LLC boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,339,522 shares of the company’s stock after purchasing an additional 111,104 shares during the quarter. Fmr LLC owned approximately 2.30% of Intellia Therapeutics worth $48,077,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. First Horizon Advisors Inc. raised its stake in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares in the last quarter. Elmwood Wealth Management Inc. increased its position in shares of Intellia Therapeutics by 0.9% during the third quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock worth $1,393,000 after purchasing an additional 600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares during the last quarter. KBC Group NV boosted its position in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares in the last quarter. Finally, Axxcess Wealth Management LLC grew its stake in Intellia Therapeutics by 5.4% during the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after buying an additional 1,044 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Stock Up 7.8 %

NTLA stock opened at $14.72 on Friday. Intellia Therapeutics, Inc. has a 52-week low of $12.82 and a 52-week high of $34.87. The company’s 50-day simple moving average is $16.61 and its 200-day simple moving average is $20.98. The firm has a market cap of $1.50 billion, a P/E ratio of -2.71 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter last year, the firm earned ($1.38) earnings per share. The firm’s quarterly revenue was down 24.1% compared to the same quarter last year. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citigroup lowered their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Stifel Nicolaus cut their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Barclays lowered their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, Chardan Capital lifted their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.